FDA Brief

Warning letters Food

FDA warning letter to

Day Light Nutrition

LowIssued Aug 4, 2023Posted Oct 3, 2023Division of Human and Animal Food Operations West II

FDA says Day Light Nutrition markets four supplement products as unapproved drugs with disease-treatment claims on its website.

What happened

FDA reviewed www.daylightnutrition.com in July 2023 and found the company takes orders there for Above the Weather, Diabetic Support Blend, Joint Well, and ViruZap. FDA cited website and label claims that the products treat or prevent diseases such as flu, cold symptoms, diabetes/glucose problems, arthritis pain and inflammation, and viral or bacterial infections. FDA determined the products are unapproved new drugs and that three of them are misbranded because their directions are not adequate for safe lay use.

What FDA found

  1. FDA says the products are drugs because the website claims they cure, mitigate, treat, or prevent disease.

    section 201(g)(1)(B) of the Act [21 U.S.C. ยง 321(g)(1)(B)]
  2. FDA says the products are "new drugs" that lack FDA approval and were offered for interstate commerce.

    section 201(p) of the Act [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  3. FDA says Above the Weather, Diabetic Support Blend, and ViruZap are misbranded because they lack adequate directions for safe use by a layperson.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. FDA says offering these misbranded drugs for interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

Within 15 working days of receipt, notify FDA in writing of the specific steps taken to address the violations and prevent recurrence, with related documentation. If corrections cannot be completed in that time, state the reason for the delay and when they will be done; if the company believes it is not in violation, include its reasoning and supporting information.

Who should pay attention

  • retailers and online marketplaces selling supplement products
  • brands making disease-related claims for supplements
  • consumers using supplements for flu, diabetes, joint pain, or infections

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk